Evaluation of microRNA-205 expression as a potential triage marker for patients with low-grade squamous intraepithelial lesions
- PMID: 28529583
- PMCID: PMC5431461
- DOI: 10.3892/ol.2017.5909
Evaluation of microRNA-205 expression as a potential triage marker for patients with low-grade squamous intraepithelial lesions
Abstract
High-risk human papillomavirus (HPV) testing is a recommended triage approach for females with atypical squamous cells of undetermined significance (ASCUS), but due to its poor specificity this approach is not recommended for patients with low-grade squamous intraepithelial lesions (LSIL). The objective of the current study was to determine microRNA (miR)-205 expression levels in liquid-based cytology (LBC) samples, and evaluate their ability to predict cervical intraepithelial neoplasia grade 2/3 or worse (CIN2/3+) in females with minor cytological abnormalities. LBC samples were obtained from patients attending the Swedish Cervical Cancer Screening Program. The Mann-Whitney U test, one-way analysis of variance, Kruskal-Wallis test, Spearman rank order correlation analysis, and Pearson's χ2 test were used to assess the results. Accuracy analyses indicated that high miR-205 expression had a significantly higher specificity to high-risk HPV testing, and a sensitivity similar to that of high-risk HPV testing to predict CIN2+ and CIN3+ in women with LSIL, but not those with high-grade squamous intraepithelial lesions. Although further research is required for females with LSIL, miR-205 expression in LBC samples may be a novel triage marker for, or a beneficial supplement to high-risk-HPV testing in these patients.
Keywords: cervical intraepithelial lesions; human papillomavirus; liquid-based cytology; microRNA-205; specificity.
Similar articles
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
-
Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.Gynecol Oncol. 2019 Aug;154(2):360-367. doi: 10.1016/j.ygyno.2019.05.012. Epub 2019 May 31. Gynecol Oncol. 2019. PMID: 31160073
-
The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.PLoS One. 2020 Jun 11;15(6):e0234518. doi: 10.1371/journal.pone.0234518. eCollection 2020. PLoS One. 2020. PMID: 32525936 Free PMC article.
-
Liquid-based cytology with HPV triage of low-grade cytological abnormalities versus conventional cytology in cervical cancer screening.Curr Pharm Des. 2013;19(8):1406-11. Curr Pharm Des. 2013. PMID: 23016773
-
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Vaccine. 2008. PMID: 18847555 Review.
Cited by
-
Role of microRNAs as biomarkers of cervical carcinogenesis: a systematic review.Obstet Gynecol Sci. 2021 Sep;64(5):419-436. doi: 10.5468/ogs.21123. Epub 2021 Aug 13. Obstet Gynecol Sci. 2021. PMID: 34384196 Free PMC article.
-
MicroRNA Biomarkers of High-Grade Cervical Intraepithelial Neoplasia in Liquid Biopsy.Biomed Res Int. 2021 Apr 13;2021:6650966. doi: 10.1155/2021/6650966. eCollection 2021. Biomed Res Int. 2021. PMID: 33954190 Free PMC article.
-
Human Papillomavirus Infections, Cervical Cancer and MicroRNAs: An Overview and Implications for Public Health.Microrna. 2020;9(3):174-186. doi: 10.2174/2211536608666191026115045. Microrna. 2020. PMID: 31738147 Free PMC article. Review.
-
Identification of Circulating MicroRNAs as a Promising Diagnostic Biomarker for Cervical Intraepithelial Neoplasia and Early Cancer: A Meta-Analysis.Biomed Res Int. 2020 Mar 23;2020:4947381. doi: 10.1155/2020/4947381. eCollection 2020. Biomed Res Int. 2020. PMID: 32280688 Free PMC article.
-
Cervical Cancer, Papillomavirus, and miRNA Dysfunction.Front Mol Biosci. 2021 Dec 10;8:758337. doi: 10.3389/fmolb.2021.758337. eCollection 2021. Front Mol Biosci. 2021. PMID: 34957212 Free PMC article. Review.
References
-
- The National Board of Health and Welfare: Cancer incidence in Sweden 2008. The National Board of Health and Welfare; Stockholm: 2009.
-
- Annual report 2014 with data to 2013. National Quality Register for Cervical Screening; Stockholm, Swedish: 2014. National Quality Register for Cervical Screening: Prevention of cervical cancer in Sweden.
LinkOut - more resources
Full Text Sources
Other Literature Sources